Conavi Medical Corp. CNVI

Latest publication adds to growing body of clinical evidence supporting hybrid IVUS-OCT imaging in complex coronary procedures Chief Technology Officer Amandeep Thind to lead continued innovation TORONTO, Sept. 17, 2026 (GLOBE NEWSWIRE) -- Conavi Medical Corp. (TSXV: CNVI) (OTCQB: CNVIF) (“Conavi” or the “Company”), a commercial-stage medical device company focused on designing, manufacturing and marketing imaging technologies to guide minimally invasive cardiovascular procedures, today announce

TORONTO, Sept. 04, 2026 (GLOBE NEWSWIRE) -- Conavi Medical Corp. (TSXV: CNVI) (OTCQB: CNVIF) (“Conavi” or the “Company”), a commercial-stage medical device company focused on designing, manufacturing, and marketing imaging technologies to guide minimally invasive cardiovascular procedures, today announced that it has entered into media and digital marketing agreements to support increased market awareness of the Company. Media and Digital Marketing Agreements Conavi Medical has entered into a me

Net loss for Fiscal Q3 2026 was $6.3 million (Fiscal Q3 2025 - $3.6 million) reflecting continued investment in research and development activities of $4.4 million (Fiscal Q3 2025 - $3.2 million) Ended Fiscal Q3 2026 with $0.9M in cash and cash equivalents (Fiscal Q4 2025 - $5.8 million) and on August 12, 2026 closed $10 million public offering Received $1.25 Million Ontario Life Sciences Scale-Up Fund Milestone PaymentAchieved U.S. FDA 510(k) Clearance for Next-Generation Hybrid IVUS-OCT Imagin

NOT FOR DISTRIBUTION TO U.S. NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES TORONTO, Aug. 12, 2026 (GLOBE NEWSWIRE) -- Conavi Medical Corp. (TSXV: CNVI) (“Conavi” or the “Company”), a commercial stage medical device company focused on designing, manufacturing, and marketing imaging technologies to guide common minimally invasive cardiovascular procedures, is pleased to announce that it has closed its previously announced equity offering for aggregate gross proceeds of $10 million (

NOT FOR DISTRIBUTION TO U.S. NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES FINAL PROSPECTUS WILL BE ACCESSIBLE ON SEDAR+ TORONTO, July 29, 2026 (GLOBE NEWSWIRE) -- Conavi Medical Corp. (TSXV: CNVI) (“Conavi” or the “Company”), a commercial stage medical device company focused on designing, manufacturing, and marketing imaging technologies to guide minimally invasive cardiovascular procedures, is pleased to announce the pricing and terms of its previously announced public offering.

Publication demonstrates how complementary IVUS and OCT information supports lesion assessment, treatment planning, and stent optimization while helping manage contrast useTORONTO, July 08, 2026 (GLOBE NEWSWIRE) -- Conavi Medical Corp. (TSXV: CNVI) (OTCQB: CNVIF) (“Conavi” or the “Company”), a commercial-stage medical device company focused on designing, manufacturing, and marketing imaging technologies to guide minimally invasive cardiovascular procedures, today announced the publication of a c

Company has received $1.75 million in total under the program, including a $1.25 million payment triggered by the Company’s U.S. FDA clearance, to support the commercial launch of its hybrid IVUS-OCT imaging systemTORONTO, June 29, 2026 (GLOBE NEWSWIRE) -- Conavi Medical Corp. (“Conavi” or the “Company”) (TSXV: CNVI; OTCQB: CNVIF), a commercial-stage medical device company focused on designing, manufacturing, and marketing imaging technologies to guide minimally invasive cardiovascular procedure

- Achieves U.S. FDA 510(k) Clearance for Next-Generation Hybrid IVUS-OCT Imaging System- Wins Multiple Industry Awards Recognizing Innovation and Leadership in Intravascular Imaging- Advances U.S. Commercial Readiness and Launch Financing Initiatives TORONTO, May 28, 2026 (GLOBE NEWSWIRE) -- Conavi Medical Corp. (TSXV: CNVI) (OTCQB: CNVIF) (“Conavi” or the “Company”), a medical device company focused on designing, manufacturing, and marketing imaging technologies to guide minimally invasive card

PRELIMINARY PROSPECTUS ACCESSIBLE ON SEDAR+ NOT FOR RELEASE OR DISTRIBUTION IN THE UNITED STATES OR FOR DISSEMINATION TO U.S. NEWS WIRE SERVICES TORONTO, May 11, 2026 (GLOBE NEWSWIRE) -- Conavi Medical Corp. (TSXV: CNVI) (“Conavi Medical” or the “Company”), a commercial stage medical device company focused on designing, manufacturing, and marketing imaging technologies to guide common minimally invasive cardiovascular procedures, announced today that it has filed a preliminary short form prospec

Recognition Follows FDA 510(k) Clearance of its Next-Generation Hybrid Intravascular Imaging SystemTORONTO, April 23, 2026 (GLOBE NEWSWIRE) -- Conavi Medical Corp. (“Conavi” or the “Company”) (TSXV: CNVI; OTCQB: CNVIF), a commercial-stage medical device company focused on designing, manufacturing, and marketing imaging technologies to guide minimally invasive cardiovascular procedures, today announced that it has been named a recipient of a 2026 TAG Award, recognizing innovation and leadership i

- First co-registered and co-aligned IVUS-OCT Platform for Intravascular Imaging - Company Positioned for U.S. Commercial Launch in a Growing Intravascular Imaging Market Estimated at Over $1 Billion TORONTO, April 20, 2026 (GLOBE NEWSWIRE) -- Conavi Medical Corp., a commercial stage medical device company focused on designing, manufacturing, and marketing imaging technologies to guide common minimally invasive cardiovascular procedures, today announced that it has received U.S. Food and Drug Ad

Toronto, Ontario--(Newsfile Corp. - April 9, 2026) - Conavi Medical Corp. (TSXV: CNVI) (OTCQB: CNVIF) ("Conavi" or the "Company"), a commercial stage medical device company focused on designing, manufacturing, and marketing imaging technologies to guide common minimally invasive cardiovascular procedures, today announced that Thomas Looby, CEO of Conavi Medical, will present and participate in one-on-one meetings at the 2026 Bloom Burton & Co. Healthcare Investor Conference to be held April 21..

TORONTO, April 02, 2026 (GLOBE NEWSWIRE) -- Conavi Medical Corp. (TSXV: CNVI; OTCQB: CNVIF) (“Conavi Medical” or the “Company”), a commercial stage medical device company focused on designing, manufacturing, and marketing imaging technologies to guide common minimally invasive cardiovascular procedures, announced today the results of its annual general meeting of shareholders held virtually on March 31, 2026 (the “Meeting”), as well as the adoption of amendments to the Company’s Stock Option Pla